Egalet Corp  

(Public, NASDAQ:EGLT)   Watch this stock  
Find more results for Jeffery J. Carlin
8.08
+0.57 (7.59%)
Feb 11 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.38 - 8.28
52 week 7.06 - 17.03
Open 7.38
Vol / Avg. 27,212.00/78,657.00
Mkt cap 193.46M
P/E     -
Div/yield     -
EPS -3.37
Shares 25.06M
Beta     -
Inst. own 89%
Mar 14, 2016
Q4 2015 Egalet Corp Earnings Release (Estimated) Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -1029.60% -2250.73%
Operating margin -923.37% -1934.17%
EBITD margin - -1900.78%
Return on average assets -42.88% -106.79%
Return on average equity -108.26% -444.79%
Employees 44 -
CDP Score - -

Address

460 E Swedesford Rd Ste 1050
WAYNE, PA 19087-1801
United States - Map
+1-610-8334200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Egalet Corporation is a specialty pharmaceutical company developing, manufacturing and commercializing medicines for patients with acute and chronic pain. The Company's products include OXAYDO and SPRIX Nasal Spray. OXAYDO is the immediate-release oxycodone product formulated to deter abuse via snorting, for the management of acute and chronic moderate to severe pain where an opioid is appropriate. SPRIX Nasal Spray is the nasal spray formulation of non-steroidal anti-inflammatory drug (NSAID), ketorolac, used for short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company is developing two late-stage product candidates using Guardian Technology. The lead program, Egalet-001 is an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002 is an abuse-deterrent, extended-release, oral oxycodone formulation.

Officers and directors

Timothy P. Walbert Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Robert Radie President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Stanley J. Musial Chief Financial Officer, Secretary
Age: 54
Bio & Compensation  - Reuters
Mark Strobeck Ph.D. Chief Operating Officer, Executive Vice President
Age: 44
Bio & Compensation  - Reuters
Paul C. Varki J.D. Senior Vice President, General Counsel
Bio & Compensation  - Reuters
Karsten Lindhardt Ph.D. Senior Vice President - Research & Development
Age: 43
Bio & Compensation  - Reuters
Barbara Carlin Chief Accounting Officer
Age: 41
Bio & Compensation  - Reuters
Jeffrey M. Dayno M.D. Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Deanne F. Melloy Chief Commercial Officer
Age: 47
Bio & Compensation  - Reuters
Jean-Fran´┐Żois Formela M.D. Director
Age: 58
Bio & Compensation  - Reuters